Lung Cancer最新文献

{"title":"Prognostic impact of lepidic growth in intermediate and high-grade lung adenocarcinoma.","authors":"Benedikt Niedermaier, Erik Rolf, Michael Allgäuer, Laura V Klotz, Marc A Schneider, Kadriya Yuskaeva, Martin E Eichhorn, Hauke Winter","doi":"10.1016/j.lungcan.2025.108674","DOIUrl":"https://doi.org/10.1016/j.lungcan.2025.108674","url":null,"abstract":"<p><strong>Background: </strong>Grade 1 lung adenocarcinomas, which are characterized by predominantly lepidic growth and less than 20 % high-risk patterns, have a favorable survival rate compared to higher-grade tumors. However, the prognostic relevance of lepidic components in intermediate and high-grade tumors (grades 2-3) remains unclear. We investigated whether lepidic growth impacts survival in grade 2-3 stage I lung adenocarcinomas.</p><p><strong>Methods: </strong>479 consecutive patients who underwent curative resection for non-mucinous lung adenocarcinoma in pathologic grade 2-3 and stage I were enrolled in this retrospective, single-center study. The impact of lepidic components and other predictors on survival was assessed in multivariable cox regression.</p><p><strong>Results: </strong>Lepidic growth was present in 300 (62.6 %) tumors. Patients with lepidic-positive tumors were significantly older (median age 67 vs. 65 years, p = 0.015), more frequently never-smokers (22.1 % vs. 9.9 %, p = 0.001), had higher proportions of acinar-predominant (69.0 % vs. 53.1 %, p = 0.001), and fewer solid-predominant tumors (7.0 % vs. 26.8 %, p < 0.001). Median follow-up was 67 months (IQR 47-92). Multivariable Cox analysis demonstrated no significant association between lepidic growth and overall or recurrence-free survival. Factors significantly affecting recurrence-free survival included age ≥ 70 years (HR 1.40, p = 0.046), stage IB (HR 1.52, p = 0.017), grade 3 tumors (HR 1.42, p = 0.040), and lymphatic invasion (HR 1.67, p = 0.011).</p><p><strong>Conclusion: </strong>Lepidic growth did not demonstrate prognostic significance in intermediate and high-grade non-mucinous lung adenocarcinoma in this study.</p>","PeriodicalId":18129,"journal":{"name":"Lung Cancer","volume":"206 ","pages":"108674"},"PeriodicalIF":4.5,"publicationDate":"2025-07-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144698958","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Prognostic impact of extracapsular extension of lymph nodes in resected lung cancer: analysis by new N subcategories and histologic types.","authors":"Yura Ahn, Shi A Kim, Sang Min Lee, Bokyung Ahn, Sehoon Choi, Kyung-Hyun Do, Joon Beom Seo","doi":"10.1016/j.lungcan.2025.108673","DOIUrl":"https://doi.org/10.1016/j.lungcan.2025.108673","url":null,"abstract":"<p><strong>Objectives: </strong>Despite being an R1 descriptor, the effects of extracapsular extension (ECE) on survival are inconsistent and remains invalidated under N2 subcategorization (pN2a and pN2b). This study aimed to validate the survival effect of ECE across N subcategories and histologic types.</p><p><strong>Materials and methods: </strong>Patients who underwent lobectomy or pneumonectomy for NSCLC between 2010 and 2022, with proven pN-positive status and Union for International Cancer Control R0 designation, were retrospectively included. Effect of ECE on overall survival (OS) and recurrence-free survival (RFS) was assessed using multivariable Cox proportional hazard models, while that on recurrence patterns (locoregional vs. distant) was assessed using Fine-Gray subdistribution hazard models.</p><p><strong>Results: </strong>Among 1713 patients included, the prevalence of ECE increased with the pN category: 11.6 % in pN1 (87/751), 17.6 % in pN2a (104/581), and 44.6 % in pN2b (170/381). ECE was an independent risk factor for poor OS and RFS in all pN-positive patients, after covariate adjustment (all p < 0.05). Patients with ECE consistently exhibited higher risks of mortality and RFS events compared to their ECE-negative counterparts across pN1, pN2a, and pN2b (all p < 0.05). Upon stratification by histologic type, ECE exhibited negative effects exclusively in adenocarcinoma (all p < 0.05), not in non-adenocarcinoma (all p > 0.05). ECE was an independent risk factor for locoregional recurrence (p = 0.002) but not for distant recurrence (p = 0.090).</p><p><strong>Conclusion: </strong>ECE demonstrated a negative effect across pN1, pN2a, and pN2b, validating its role as an R1 descriptor. The negative effect of ECE exclusively in adenocarcinoma highlights the need to interpret ECE status with respect to histology.</p>","PeriodicalId":18129,"journal":{"name":"Lung Cancer","volume":"206 ","pages":"108673"},"PeriodicalIF":4.5,"publicationDate":"2025-07-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144690674","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Serum mesothelin as a response biomarker in pleural mesothelioma.","authors":"Geraldine A Lynch, Jenny Symonds, Anna Morley, Emeka Azubuike-Dyer, Will Cooper, Anthony Edey, Duneesha De Fonseka, Selina Tsim, Kevin Blyth, Paul White, Nick A Maskell, Anna Bibby","doi":"10.1016/j.lungcan.2025.108670","DOIUrl":"https://doi.org/10.1016/j.lungcan.2025.108670","url":null,"abstract":"<p><strong>Background: </strong>CT scans are the current gold standard for disease monitoring for Pleural mesothelioma (PM), with radiology reported using the modified RECIST criteria. While mRECIST has its own challenges, attending for CT scans adds time and expense. A blood-based biomarker which tracks disease status could enable more responsive, community-based disease monitoring. This study evaluated the relationship between serial serum mesothelin (SM) levels and disease status.</p><p><strong>Methods: </strong>Patients with PM were recruited from Assess-Meso, a multi-centre prospective cohort study of patients with mesothelioma, between 28/2/2019 and 31/12/2023. Logistic regression, adjusted for sex, age, histology, performance status, eGFR and treatment, was used to assess the relationship between serial SM and radiological disease status. Prespecified sub-group analyses stratified participants by initial SM and treatment status.</p><p><strong>Results: </strong>156 patients had ≥ 2 SM measurements with paired CT scans. Rising SM was associated with disease progression in the coincident time period (Adj OR 1.11, 95 % CI 1.03-1.19) and the subsequent 6 months (Adj OR 1.13, 1.03-1.23), regardless of initial SM. A 25 % change in SM was the optimal threshold, with a 25 % rise associated with disease progression (Adj OR 2.68 (1.52-4.73)) with sensitivity and specificity of 48.7 % (43.1 %-54.4 %) and 75.7 % (70.8 %-80.5 %) respectively. For patients receiving treatment, falling SM predicted subsequent disease response (Adj OR 1.37, 1.16-1.61).</p><p><strong>Conclusions: </strong>Serial SM is a reliable response biomarker in PM, regardless of initial value and treatment status. These results support the use of SM in routine clinical care as an adjunct to CT scans, with several benefits over radiological monitoring.</p>","PeriodicalId":18129,"journal":{"name":"Lung Cancer","volume":"206 ","pages":"108670"},"PeriodicalIF":4.5,"publicationDate":"2025-07-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144667926","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Cost-effectiveness and budget impact of lung cancer screening in time of immunotherapy","authors":"Danrong Zhong ,&nbsp;Grigory Sidorenkov ,&nbsp;Keris Poelhekken ,&nbsp;Yihui Du ,&nbsp;Karin M. Vermeulen ,&nbsp;Rozemarijn Vliegenthart ,&nbsp;Marjolein A. Heuvelmans ,&nbsp;Harry J.M. Groen ,&nbsp;Marcel J.W. Greuter ,&nbsp;Geertruida H. de Bock","doi":"10.1016/j.lungcan.2025.108669","DOIUrl":"10.1016/j.lungcan.2025.108669","url":null,"abstract":"<div><h3>Background</h3><div>Lung cancer screening in high-risk populations with low-dose computed tomography (LDCT) reduces lung cancer mortality by detecting cancer at early stage. Immunotherapy improves survival in these patients. This study evaluates the cost-effectiveness and budget impact of LDCT screening extending immunotherapy to early-stage patients.</div></div><div><h3>Methods</h3><div>A micro-simulation model Simulation Model on Radiation Risk and cancer Screening (SiMRiSc, validated against NELSON results) was used to a Dutch heavy smokers cohort. Average cost-effectiveness ratio (ACER), lung cancer mortality reduction, and budget impact of biennial screening for heavy smokers aged 55–74 (adapted from the UK strategy) were evaluated in context of immunotherapy, compared with no-screening. A cost-effectiveness threshold was set at 60 k€ per life year gained (LYG).</div></div><div><h3>Results</h3><div>Compared with no-screening, limiting immunotherapy to advanced-stage patients, screening resulted in ACERs of 4.7 k€/LYG for males and 6.6 k€/LYG for females, reducing lung cancer mortality by 18.1 % and 17.1 %, respectively. Extending immunotherapy to all stages increased ACERs to 5.2 k€/LYG for males and 7.1 k€/LYG for females, with lung cancer mortality reduction of 21.1 % and 20.1 %, respectively. Budget impact analysis shows screening saved 35–52 million€ when immunotherapy restricted to advanced-stage, and 24–39 million€ for all stages immunotherapy over three-screening rounds compared with no-screening, primarily due to a 53 % reduction for advanced-stage cases.</div></div><div><h3>Conclusion</h3><div>Lung cancer screening in high-risk population remains cost-effective when immunotherapy is offered to all stages. By shifting diagnoses from advanced to early stages, screening yielding substantial savings. These findings support LDCT screening implementation even in healthcare systems broadly using immunotherapy.</div></div>","PeriodicalId":18129,"journal":{"name":"Lung Cancer","volume":"206 ","pages":"Article 108669"},"PeriodicalIF":4.5,"publicationDate":"2025-07-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144655036","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Safety, efficacy, and analysis of biomarkers in patients with advanced non-small cell lung cancer treated with the anti-IL1RAP antibody nadunolimab (CAN04) in combination with platinum doublet","authors":"Astrid Paulus ,&nbsp;Marius Zemaitis ,&nbsp;Saulius Cicenas ,&nbsp;Zanete Zvirbule ,&nbsp;Annika Sanfridson ,&nbsp;Camilla Rydberg Millrud ,&nbsp;Susanne Magnusson ,&nbsp;Nedjad Losic ,&nbsp;Dominique Tersago ,&nbsp;Ignacio Garcia-Ribas ,&nbsp;Lars Thorsson ,&nbsp;Luis G. Paz-Ares","doi":"10.1016/j.lungcan.2025.108664","DOIUrl":"10.1016/j.lungcan.2025.108664","url":null,"abstract":"<div><h3>Introduction</h3><div>Interleukin-1 receptor accessory protein (IL1RAP), expressed in several tumors, is essential for IL-1α and IL-1β signaling which leads to tumor progression and treatment resistance. Nadunolimab, a fully humanized antibody-dependent cellular cytotoxicity-enhanced monoclonal antibody, targets IL1RAP and blocks IL-1α/IL-1β signaling. Efficacy and safety of nadunolimab plus platinum-based doublet chemotherapies were assessed in patients with non-small cell lung cancer (NSCLC) (NCT03267316).</div></div><div><h3>Methods</h3><div>Patients with advanced NSCLC received nadunolimab plus platinum-based doublet chemotherapies in first-line or second-line post-pembrolizumab. Study objectives included the anti-tumor response, progression-free survival (PFS), overall survival (OS), levels of biomarkers in serum, and immunohistochemistry of baseline and on-treatment tumor biopsies.</div></div><div><h3>Results</h3><div>43 patients were enrolled, median age 64 years, 38 % female, and 43 % were treated in second-line post-pembrolizumab. Median PFS was 7.2 months (95 % CI 5.6–9.2), median OS was 13.7 months (95 % CI 11.1–18.3), and 1-year survival was 54 %. The greatest benefits were observed in 11 patients with non-squamous histology treated in second-line post-pembrolizumab: median OS 26.7 months, ORR 91 % including two complete responders (with distinct biomarker profiles), and 1-year survival 82 %. Biomarker analyses showed that patients in second-line post-pembrolizumab had an enhanced level of tumor-infiltrating immune cells compared to treatment naïve patients. Rates of Grade 3+ neutropenia, anemia, and thrombocytopenia were higher than previous reports of platinum-based doublet chemotherapies alone.</div></div><div><h3>Conclusions</h3><div>Nadunolimab plus platinum-based doublet chemotherapies showed promising efficacy in advanced NSCLC, with the greatest benefit in patients with non-squamous histology treated in second line after relapsing on pembrolizumab treatment.</div></div>","PeriodicalId":18129,"journal":{"name":"Lung Cancer","volume":"206 ","pages":"Article 108664"},"PeriodicalIF":4.5,"publicationDate":"2025-07-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144655035","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"An introduction to pragmatic trials in lung cancer research: A multi-faceted approach","authors":"Sarah Bowen Jones ,&nbsp;Gareth Price ,&nbsp;Corinne Faivre-Finn","doi":"10.1016/j.lungcan.2025.108663","DOIUrl":"10.1016/j.lungcan.2025.108663","url":null,"abstract":"<div><div>Pragmatic clinical trials (PTs) are increasingly recognised as a key methodology in lung cancer research, designed to evaluate the effectiveness of interventions in routine clinical settings. In contrast to traditional randomised controlled trials (RCTs), which involve highly selected patient populations under ideal conditions, PTs enrol broader, more representative cohorts, use streamlined trial procedures, and focus on outcomes that reflect patient-centred priorities. This enhances the generalisability of the results and supports evidence-based, joint decision-making between patients and clinicians. PTs offer a more sustainable and scalable path to generate clinically meaningful evidence that improves the quality of patient care and can address longstanding evidence gaps in the management of patients with lung cancer.</div><div>This narrative review outlines the main features of PTs, highlighting the PRECIS-2 tool as a framework to design and evaluate the degree of pragmatism of a trial. Common challenges in clinical trial design — including recruitment of participants, informed consent, selection of appropriate clinical endpoints, data quality — are discussed alongside practical solutions. The emerging role of PTs in generating regulatory-grade evidence and the impact of PTs on clinical guidelines is discussed. Ongoing PTs are outlined, which demonstrate how pragmatic methodologies can be used to the evaluate screening interventions, therapeutic strategies and models of care delivery across a range of clinical settings.</div></div>","PeriodicalId":18129,"journal":{"name":"Lung Cancer","volume":"206 ","pages":"Article 108663"},"PeriodicalIF":4.5,"publicationDate":"2025-07-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144605453","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Corrigendum to \"Sex disparities in advanced non-small cell lung cancer survival: A Danish nationwide study\" [Lung Cancer 202 (2025) 108485].","authors":"Matilde Grupe Frost, Kristoffer Jarlov Jensen, Espen Jimenez-Solem, Camilla Qvortrup, Jon Alexander Lykkegaard Andersen, Tonny Studsgaard Petersen","doi":"10.1016/j.lungcan.2025.108658","DOIUrl":"https://doi.org/10.1016/j.lungcan.2025.108658","url":null,"abstract":"","PeriodicalId":18129,"journal":{"name":"Lung Cancer","volume":" ","pages":"108658"},"PeriodicalIF":4.5,"publicationDate":"2025-07-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144600932","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Corrigendum to \"AGREE-II appraisal of lung cancer management clinical practice guidelines by the OPTIMA consortium\". [Lung Cancer 205 (2025) 108610].","authors":"Sindhu Bhaarrati Naidu, Amyn Bhamani, Charlotte Murray, Katharina Beyer, Rebecca C Rancourt, Thorben Witte, Wouter H van Geffen, Ilona Tietzova, Armin Frille, Adrien Costantini, Monika Schäfer, Steven MacLennan, Hagen Krüger, Solveiga Žibaitė, James N'Dow, Sara Jane MacLennan, Monique J Roobol, Sam M Janes, Neal Navani, Muhammad Imran Omar, Torsten Blum","doi":"10.1016/j.lungcan.2025.108659","DOIUrl":"10.1016/j.lungcan.2025.108659","url":null,"abstract":"","PeriodicalId":18129,"journal":{"name":"Lung Cancer","volume":" ","pages":"108659"},"PeriodicalIF":4.5,"publicationDate":"2025-07-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144600931","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Disparities in adherence to guideline-concordant care and receipt of immunotherapy for Non-Small cell lung cancer in the United States","authors":"Ian Nykaza ,&nbsp;Anjile An ,&nbsp;Jonathan Villena-Vargas ,&nbsp;Lauren Mount ,&nbsp;Nasser K Altorki ,&nbsp;Rulla M Tamimi","doi":"10.1016/j.lungcan.2025.108661","DOIUrl":"10.1016/j.lungcan.2025.108661","url":null,"abstract":"<div><h3>Background</h3><div>Significant progress has been made in reducing lung cancer mortality in the United States, largely due to decreased smoking rates and advancements in treatment, particularly for non-small cell lung cancer (NSCLC). However, lung cancer remains the leading cause of cancer-related deaths, with an estimated 127,010 deaths in 2023. Disparities persist in lung cancer incidence, screening, and treatment, influenced by factors such as race, ethnicity, socioeconomic status, and geography.</div></div><div><h3>Methods</h3><div>This study analyzed NSCLC treatment patterns in 302,744 patients from the National Cancer Database (NCDB) diagnosed between 2015–2018, focusing on adherence to National Comprehensive Cancer Network (NCCN) guidelines and disparities in immunotherapy receipt.</div></div><div><h3>Results</h3><div>Overall, 62% of patients received guideline-concordant treatment, though this varied significantly by stage, with only 54% of stage IV patients receiving appropriate care. Disparities in guideline adherence were observed, particularly among non-Hispanic Black patients, elderly individuals, and uninsured or Medicaid-covered patients. Additionally, patients at academic institutions and high-volume facilities were more likely to receive concordant treatment, whereas those at community cancer programs and minority-serving hospitals (MSH) had lower adherence rates. Immunotherapy, increasingly recommended since 2017, was also less accessible to non-Hispanic Black, Hispanic, and Asian patients, those without private insurance, elderly individuals, and patients receiving treatment at MSH institutions.</div></div><div><h3>Conclusions</h3><div>These findings highlight the need for targeted interventions to address persistent disparities in lung cancer treatment, present from individual to institutional levels, in order to ensure equitable access to recommended treatments and advanced therapies like immunotherapy.</div></div>","PeriodicalId":18129,"journal":{"name":"Lung Cancer","volume":"206 ","pages":"Article 108661"},"PeriodicalIF":4.5,"publicationDate":"2025-07-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144632363","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Value of 18F-FDG PET metabolic parameters combined with the dynamic monitoring of molecular residual disease (MRD) in predicting the prognosis of non-small-cell lung cancer after surgery","authors":"You Cheng ,&nbsp;Guo-Jian Huang ,&nbsp;Xiao-bo Chen ,&nbsp;Hao-yu Zhu ,&nbsp;Kai-yu Lu ,&nbsp;Fan Yang ,&nbsp;Jia-tao Zhang ,&nbsp;Zai-yi Liu ,&nbsp;Dan Shao","doi":"10.1016/j.lungcan.2025.108660","DOIUrl":"10.1016/j.lungcan.2025.108660","url":null,"abstract":"<div><h3>Objective</h3><div>To study the ability of the combination of ¹⁸F-FDG positron-emission tomography/computed tomography (PET/CT) metabolic parameters and the dynamic monitoring of molecular residual disease (MRD) in predicting the prognosis of non-small-cell lung cancer (NSCLC) after surgery.</div></div><div><h3>Methods</h3><div>The clinical data and disease-free survival (DFS) data of 157 NSCLC patients who underwent ¹⁸F-FDG PET/CT at 2 weeks before surgery and were regularly monitored for MRD after surgery were retrospectively analyzed. The correlation between PET metabolic parameters and the dynamic monitoring of MRD and the values of the two in predicting prognosis of NSCLC were analyzed.</div></div><div><h3>Results</h3><div>Survival analysis revealed that patients with elevated ¹⁸F-FDG PET metabolism had a worse prognosis, while MRD-positive patients had a significantly worse prognosis than MRD-negative patients. By combining of PET metabolic parameters and MRD status, the PET-high-metabolism + MRD-positive group had a worse prognosis than the PET-high-metabolism + MRD-negative group or the PET-low-metabolism + MRD-positive group and the PET-low-metabolism + MRD-negative group. The prognostic model established by tumor TNM staging, clinical data and PET metabolic parameters(comd 1 model) had a high predictive value (C-index: 0.759, 95 % CI: 0.683–0.835). After adding this model to the MRD detection results(comd 2 model), the prognostic accuracy of the model improved (C-index: 0.873, 95 % CI: 0.824–0.922).</div></div><div><h3>Conclusion</h3><div>The prognostic model made up of Tumor TNM staging,¹⁸F-FDG PET metabolic parameters and clinical data can accurately predict recurrence in NSCLC patients after surgery. Incorporating the results of the dynamic monitoring of MRD detection into the model can significantly enhance its the prognostic accuracy.</div></div>","PeriodicalId":18129,"journal":{"name":"Lung Cancer","volume":"206 ","pages":"Article 108660"},"PeriodicalIF":4.5,"publicationDate":"2025-07-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144570404","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}